IPC 7 English version C07D 501/00-C07D 521/00

C07D50100-C07D52100

SECTION C – CHEMISTRY; METALLURGY

C 07

ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B 33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B 3/00, C25B 7/00) [2]

C 07 D

HETEROCYCLIC COMPOUNDS [2]

501/

Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring [2]

501/

Preparation [2]

501/

from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents [2]

501/

Acylation of 7-aminocephalosporanic acid [2]

501/

by forming the ring or condensed ring systems (by microbiological processes C12P 35/00) [2]

501/

from compounds containing the penicillin ring system [2]

501/

Separation; Purification [2]

501/

Compounds having a nitrogen atom directly attached in position 7 [2]

501/

with a double bond between positions 2 and 3 [2]

501/

7-Aminocephalosporanic or substituted 7-aminocephalosporanic acids [2]

501/

7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids [2]

501/

with radicals containing only hydrogen and carbon atoms, attached in position 3 [2]

501/

with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3 [2]

501/

Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group [2]

501/

with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms [2]

501/

with the 7-amino-radical acylated by an araliphatic carboxylic acid [2]

501/

with the 7-amino radical acylated by an araliphatic carboxylic acid, which is substituted on the aliphatic radical by hetero atoms [2]

501/

with the 7-amino radical acylated by carboxylic acids containing hetero rings [2]

501/

Methylene radicals, substituted by sulfur atoms [2]

501/

Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof [2]

501/

with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms [2]

501/

with the 7-amino radical acylated by an araliphatic carboxylic acid [2]

501/

with the 7-amino radical acylated by an araliphatic carboxylic acid, which is substituted on the aliphatic radical by hetero atoms [2]

501/

with the 7-amino radical acylated by carboxylic acids containing hetero rings [2]

501/

Methylene radicals, substituted by hetero rings (C07D 501/38 to C07D 501/46 take precedence) [2]

501/

with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms [2]

501/

with the 7-amino radical acylated by an araliphatic carboxylic acid [2]

501/

with the 7-amino radical acylated by an araliphatic carboxylic acid, which is substituted on the aliphatic radical by hetero atoms [2]

501/

with the 7-amino radical acylated by carboxylic acids containing hetero rings [2]

501/

with a further substituent in position 7, e.g. cephamycines [3]

501/

with a nitrogen atom, which is a member of a hetero ring, attached in position 7 [2]

501/

with hetero atoms directly attached in position 3 [3]

501/

with a double bond between positions 3 and 4 [2]

501/

Compounds further condensed with a carbocyclic ring or ring system [3]

503/

Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring [6]

503/

Preparation (by microbiological processes C12P 17/18) [6]

503/

by forming the ring or condensed ring systems [6]

503/

from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents [6]

503/

Modification of a carboxyl group directly attached in position 2, e.g. esterification [6]

503/

with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 [6]

503/

unsubstituted in position 6 [6]

503/

with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, other than a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, attached in position 3 [6]

503/

Radicals substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical [6]

503/

by oxygen atoms [6]

503/

by sulfur atoms [6]

503/

by nitrogen atoms [6]

505/

Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring [6]

505/

Preparation (by microbiological processes C12P 17/18) [6]

505/

by forming the ring or condensed ring systems [6]

505/

from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents [6]

505/

Modification of a carboxyl group directly attached in position 2, e.g. esterification [6]

505/

with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 [6]

505/

substituted in position 7 [6]

505/

with hetero atoms directly attached in position 7 [6]

505/

Nitrogen atoms [6]

505/

further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof [6]

505/

with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen [6]

505/

further substituted by singly-bound nitrogen atoms [6]

505/

further substituted by doubly-bound nitrogen atoms [6]

507/

Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups C07D 463/00, C07D 477/00 or C07D 499/00 to C07D 505/00; Such ring systems being further condensed [6]

507/

containing 3-oxa-1-azabicyclo [3.2.0] heptane ring systems [6]

507/

containing 2-oxa-1-azabicyclo [4.2.0] octane ring systems [6]

507/

containing 3-oxa-1-azabicyclo [4.2.0] octane ring systems [6]

507/

containing 4-oxa-1-azabicyclo [4.2.0] octane ring systems [6]

513/

Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D 463/00, C07D 477/00 or C07D 499/00 to C07D 507/00 [2,6]

513/

in which the condensed system contains two hetero rings [2]

513/

Ortho-condensed systems [2]

513/

Peri-condensed systems [2]

513/

Bridged systems [2]

513/

Spiro-condensed systems [2]

513/

in which the condensed system contains three hetero rings [2]

513/

Ortho-condensed systems [2]

513/

Peri-condensed systems [2]

513/

Bridged systems [2]

513/

Spiro-condensed systems [2]

513/

in which the condensed system contains four or more hetero rings [2]

515/

Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D 463/00, C07D 477/00 or C07D 499/00 to C07D 507/00 [2]

515/

in which the condensed system contains two hetero rings [2]

515/

Ortho-condensed systems [2]

515/

Peri-condensed systems [2]

515/

Bridged systems [2]

515/

Spiro-condensed systems [2]

515/

in which the condensed system contains three hetero rings [2]

515/

Ortho-condensed systems [2]

515/

Peri-condensed systems [2]

515/

Bridged systems [2]

515/

Spiro-condensed systems [2]

515/

in which the condensed system contains four or more hetero rings [2]

517/

Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms [2]

517/

in which the condensed system contains two hetero rings [2]

517/

Ortho-condensed systems [2]

517/

Peri-condensed systems [2]

517/

Bridged systems [2]

517/

Spiro-condensed systems [2]

517/

in which the condensed system contains three hetero rings [2]

517/

Ortho-condensed systems [2]

517/

Peri-condensed systems [2]

517/

Bridged systems [2]

517/

Spiro-condensed systems [2]

517/

in which the condensed system contains four or more hetero rings [2]

519/

Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D 453/00 or C07D 455/00 [2]

519/

Ergot alkaloids of the cyclic peptide type [2]

519/

Dimeric indole alkaloids, e.g. vincaleucoblastine [2]

519/

containing at least one condensed beta-lactam ring system, provided for by groups C07D 463/00, C07D 477/00 or C07D 499/00 to C07D 507/00, e.g. a penem or a cepham system [6]

521/

Heterocyclic compounds containing unspecified hetero rings [2]

C07D 493/00 - C07D 499/90